Abstract
The mucosal administration of vaccines is an area currently receiving a high level of interest due to potential advantages offered by this technique. These advantages include the ability to administer vaccines without need for needles, thus improving patient compliance with vaccination schedules, and the capacity to induce immune responses capable of preventing infections at the site of acquisition. Despite these advantages a number of limitations exist which currently inhibit our ability to successfully develop new mucosal vaccines. As such, much research is currently focused on developing new adjuvants and delivery systems to overcome these difficulties. However, despite high levels of interest in this area, relatively few mucosal vaccine candidates have successfully progressed to human clinical trials. In the review that follows, we aim to provide the reader with an overview of the immune system with respect to induction of mucosal immune responses. Furthermore, the review provides an overview of a number of microbial (bacterial toxins, CpG DNA, cytokines / chemokines, live vectors, and virus like particles) and synthetic (microspheres, liposomes, and lipopeptides) strategies that have been investigated as adjuvants or delivery systems for mucosal vaccine development, with a focus on the delivery of vaccines via the oral route.
Keywords: mucosal immunisation, mucosal adjuvants, immunology, vaccine delivery, microparticulates
Current Drug Delivery
Title: Mucosal Immunisation: Adjuvants and Delivery Systems
Volume: 1 Issue: 4
Author(s): P. M. Moyle, R. P. McGeary, J. T. Blanchfield and I. Toth
Affiliation:
Keywords: mucosal immunisation, mucosal adjuvants, immunology, vaccine delivery, microparticulates
Abstract: The mucosal administration of vaccines is an area currently receiving a high level of interest due to potential advantages offered by this technique. These advantages include the ability to administer vaccines without need for needles, thus improving patient compliance with vaccination schedules, and the capacity to induce immune responses capable of preventing infections at the site of acquisition. Despite these advantages a number of limitations exist which currently inhibit our ability to successfully develop new mucosal vaccines. As such, much research is currently focused on developing new adjuvants and delivery systems to overcome these difficulties. However, despite high levels of interest in this area, relatively few mucosal vaccine candidates have successfully progressed to human clinical trials. In the review that follows, we aim to provide the reader with an overview of the immune system with respect to induction of mucosal immune responses. Furthermore, the review provides an overview of a number of microbial (bacterial toxins, CpG DNA, cytokines / chemokines, live vectors, and virus like particles) and synthetic (microspheres, liposomes, and lipopeptides) strategies that have been investigated as adjuvants or delivery systems for mucosal vaccine development, with a focus on the delivery of vaccines via the oral route.
Export Options
About this article
Cite this article as:
Moyle M. P., McGeary P. R., Blanchfield T. J. and Toth I., Mucosal Immunisation: Adjuvants and Delivery Systems, Current Drug Delivery 2004; 1 (4) . https://dx.doi.org/10.2174/1567201043334588
DOI https://dx.doi.org/10.2174/1567201043334588 |
Print ISSN 1567-2018 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5704 |
Call for Papers in Thematic Issues
Advances of natural products, bio-actives and novel drug delivery system against emerging viral infections
Due to the increasing prevalence of viral infections and the ability of these human pathogens to develop resistance to current treatment strategies, there is a great need to find and develop new compounds to combat them. These molecules must have low toxicity, specific activity and high bioavailability. The most suitable ...read more
Electrospun Fibers as Drug Delivery Systems
In recent years, electrospun fibers have attracted considerable attention as potential platforms for drug delivery due to their distinctive properties and adaptability. These fibers feature a notable surface area-to-volume ratio and can be intentionally designed with high porosity, facilitating an increased capacity for drug loading and rendering them suitable for ...read more
Emerging Nanotherapeutics for Mitigation of Neurodegenerative Disorders
Conditions affecting the central nervous system (CNS) present a significant hurdle due to limited access of both treatments and diagnostic tools for the brain. The blood-brain barrier (BBB) acts as a barrier, restricting the passage of molecules from the bloodstream into the brain. The most formidable challenge facing scientists is ...read more
Nanotechnology Based Chemotherapy for the treatment of Head & Neck Cancer
The escalating recurrence rates observed in Head and Neck cancer, particularly within the chemo-therapeutically treated cohort (50-60%), can be attributed to the non-selective nature of current anticancer drug delivery modalities. In this context, nanotechnology-based drug delivery systems emerge as a promising avenue for achieving precise localization of therapeutic agents to ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Antibodies Against G-Protein Coupled Receptors: Novel Uses in Screening and Drug Development
Combinatorial Chemistry & High Throughput Screening Clinical Pharmacology of Novel Selective COX-2 Inhibitors
Current Pharmaceutical Design Chitinases: Biomarkers for Human Diseases
Protein & Peptide Letters Thermosensitive Polymeric Hydrogels As Drug Delivery Systems
Current Medicinal Chemistry Extensive Phytochemistry, Comprehensive Traditional Uses, and Critical Pharmacological Profile of the Great Mullein: Verbascum thapsus L
The Natural Products Journal Partners in Crime: NGF and BDNF in Visceral Dysfunction
Current Neuropharmacology Properties of the Mesenchymal Endometriotic Stem Cell in the Context of the Immune System and Analysis of its Role in Endometriosis
Recent Patents on Regenerative Medicine Targeted Enzyme Prodrug Therapies
Mini-Reviews in Medicinal Chemistry Serum miR-372 is a Diagnostic and Prognostic Biomarker in Patients with Early Colorectal Cancer
Anti-Cancer Agents in Medicinal Chemistry Role of Unani Medicines in Cancer Control and Management
Current Drug Therapy Low Dose Aspirin, COX-Inhibition and Chemoprevention of Colorectal Cancer
Current Topics in Medicinal Chemistry Recent Advances in the Design and Synthesis of Prednisolone and Methylprednisolone Conjugates
Current Pharmaceutical Design Improvement of Nutritional Qualities of Fermented Kernels of Wild Legume Canavalia cathartica by Rhizopus oligosporus
Current Biochemical Engineering (Discontinued) Control of Neuropathic Pain by Immune Cells and Opioids
CNS & Neurological Disorders - Drug Targets Monoclonal Antibodies as Innovative Therapeutics
Current Pharmaceutical Biotechnology Clinically Relevant Genetic Variations in Drug Metabolizing Enzymes
Current Drug Metabolism Anti-Infective Protective Properties of S100 Calgranulins
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Using Pharmacologic Data to Plan Clinical Treatments for Patients with Peritoneal Surface Malignancy
Current Drug Discovery Technologies Monoclonal Antibody-based Genetic Immunotherapy
Current Gene Therapy HHT in Childhood: Screening for Special Patients
Current Pharmaceutical Design